Novabay Pharmaceuticals Inc SMA 50
What is the SMA 50 of Novabay Pharmaceuticals Inc?
The SMA 50 of Novabay Pharmaceuticals Inc is $1 -68.74%
What is the definition of SMA 50?
SMA 50 is an average stock price from the last 50 days calculated as an unweighted mean of the previous 50 stock closing prices.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 of companies in the Health Care sector on NYSEMKT compared to Novabay Pharmaceuticals Inc
What does Novabay Pharmaceuticals Inc do?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Companies with sma 50 similar to Novabay Pharmaceuticals Inc
- Teuton Resources has SMA 50 of $1 +18.84%
- Spark Power has SMA 50 of CAD$1 +1.88%
- AirNet Technology has SMA 50 of $1 -136.76%
- Arts Optical International has SMA 50 of $1 -0.94%
- Future Enterprises has SMA 50 of ₨1 +13.10%
- Solitario Resources Corp has SMA 50 of $1 -13.64%
- Novabay Pharmaceuticals Inc has SMA 50 of $1 -68.74%
- ImmunoPrecise Antibodies has SMA 50 of $1 -27.46%
- EVRAZ Plc has SMA 50 of GBX1 +99.00%
- Galeo Concept SA has SMA 50 of €1 +53.71%
- ESG Capital 1 has SMA 50 of CAD$1 -35.00%
- Acorn Capital Investment Fund has SMA 50 of AUD$1 -0.76%
- China Molybdenum Co has SMA 50 of $1 -17.57%